Finding the best combination of drugs for curing vivax malaria in the Solomon Islands

Phase 4

Completed

• Conditions: Plasmodium vivax malaria; Infection - Other infectious diseases

• Registration Number: ACTRN12617000329369
• Lead Sponsor: The Walter and Eliza Hall Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-02
• Study Completion: 2019-08-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 383

Inclusion Criteria

1.Age over 12 months
2.Weight greater than or equal to 10kg
3.Melanesian background and living in local area
4.Microscopically (based on field microscopy) or RDT confirmed P.vivax regardless of parasite density. Mixed infections (P.falciparum-P.vivax) can be included.

Exclusion Criteria

1.Any signs of severe malaria (see WHO definitions) including: impaired consciousness, respiratory distress, severe anaemia (Hb<5), multiple seizures, frequent vomiting/ inability to swallow tablets, prostration, jaundice, hypotension, abnormal bleeding or hypoglycaemia.
2.Clinical evidence of non-malarial illness (such as pneumonia or otitis media)
3.Severe malnutrition (weight-for-age nutritional Z score [WAZ] <60th percentile)
4.Permanent disability, which prevents or impedes study participation.
5.Treatment with PQ in the previous 14 days
6.Residence or planned travel outside the study area during the follow-up period (precluding supervised treatment and follow-up procedures)
7.Known or suspected pregnancy
8.Currently breastfeeding
9.A positive rapid test for G6PD deficiency (Binax (Trademark) or Carestart (Trademark) RDT)

Study & Design

• Study Type: Interventional
• Study Design: Not specified